Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts quarterly revenue above estimates, shares rise
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- NVIDIA (NVDA) Tops Q2 EPS by 14c, Offers Guidance
Insys Therapeutics (INSY) Tops Q4 EPS by 3c
April 3, 2017 6:55 AM EDTInsys Therapeutics (NASDAQ: INSY) reported Q4 EPS of $0.03, $0.03 better than the analyst estimate of $0.00. Revenue for the quarter came in at $54.9 million versus the consensus estimate of $51.15 million.
For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.
... More